A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies
Latest Information Update: 15 Nov 2021
At a glance
- Drugs VG 161 (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Virogin Biotech
Most Recent Events
- 08 Jun 2021 Status changed from not yet recruiting to recruiting, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results (n=3) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 03 Mar 2020 New trial record